401 related articles for article (PubMed ID: 18162241)
41. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
[TBL] [Abstract][Full Text] [Related]
42. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?
Günther OP; Ogilvie G; Naus M; Young E; Patrick DM; Dobson S; Duval B; Noël PA; Marra F; Miller D; Brunham RC; Pourbohloul B
J Infect Dis; 2008 Jun; 197(12):1653-61. PubMed ID: 18513154
[TBL] [Abstract][Full Text] [Related]
43. Vaccines for the prevention of human papillomavirus infections.
Speck LM; Tyring SK
Skin Therapy Lett; 2006; 11(6):1-3. PubMed ID: 16912836
[TBL] [Abstract][Full Text] [Related]
44. New quadrivalent HPV vaccine developments.
Tovar JM; Bazaldua OV
Postgrad Med; 2008 Nov; 120(4):14-6. PubMed ID: 19020361
[TBL] [Abstract][Full Text] [Related]
45. Measuring serum antibody to human papillomavirus following infection or vaccination.
Frazer IH
Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
[TBL] [Abstract][Full Text] [Related]
46. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
Harper DM
Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
[TBL] [Abstract][Full Text] [Related]
47. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.
Lehtinen M; Idänpään-Heikkilä I; Lunnas T; Palmroth J; Barr E; Cacciatore R; Isaksson R; Kekki M; Koskela P; Kosunen E; Kuortti M; Lahti L; Liljamo T; Luostarinen T; Apter D; Pukkala E; Paavonen J
Int J STD AIDS; 2006 Apr; 17(4):237-46. PubMed ID: 16595046
[TBL] [Abstract][Full Text] [Related]
48. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
49. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
[TBL] [Abstract][Full Text] [Related]
50. Post-licensure monitoring of HPV vaccine in the United States.
Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
[TBL] [Abstract][Full Text] [Related]
51. Prevention strategies against human papillomavirus in males.
Garland SM
Gynecol Oncol; 2010 May; 117(2 Suppl):S20-5. PubMed ID: 20138347
[TBL] [Abstract][Full Text] [Related]
52. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
53. Human papillomavirus vaccine: widening the scope for cancer prevention.
No JH; Kim MK; Jeon YT; Kim YB; Song YS
Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
[TBL] [Abstract][Full Text] [Related]
54. Long-term efficacy of human papillomavirus vaccination.
Ault KA
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S27-30. PubMed ID: 17938016
[TBL] [Abstract][Full Text] [Related]
55. Prevalence and incidence of HPV genital infection in women.
Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
[TBL] [Abstract][Full Text] [Related]
56. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
57. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
58. Human papillomavirus vaccines: an update for gynecologists.
Ault KA
Clin Obstet Gynecol; 2008 Sep; 51(3):527-32. PubMed ID: 18677145
[TBL] [Abstract][Full Text] [Related]
59. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence.
Bonanni P; Boccalini S; Bechini A
Vaccine; 2009 May; 27 Suppl 1():A46-53. PubMed ID: 19480962
[TBL] [Abstract][Full Text] [Related]
60. Vaccines for preventing HPV-related anogenital infection and neoplasia.
Ferris DG
J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]